Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genscript Biotech ( (HK:1548) ) just unveiled an update.
Genscript Biotech Corporation has scheduled a board meeting for 15 March 2026 to review and approve its annual results for the year ended 31 December 2025. The board will also decide on the publication of these results and consider whether to declare an annual dividend, signaling a forthcoming update on the company’s financial performance and potential shareholder returns.
The most recent analyst rating on (HK:1548) stock is a Sell with a HK$13.00 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.
More about Genscript Biotech
Genscript Biotech Corporation, incorporated in the Cayman Islands and listed in Hong Kong under stock code 1548, operates in the biotechnology sector. The company is governed by a board comprising executive and independent non-executive directors, reflecting a typical listed-company governance structure focused on global biotech markets.
Average Trading Volume: 8,952,850
Technical Sentiment Signal: Sell
Current Market Cap: HK$24.56B
For detailed information about 1548 stock, go to TipRanks’ Stock Analysis page.